Evidence map›Paper›PMID 37399757›Full record

ArticleJournal of psychiatric research2023

Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT.

Rebecca E Lubin, Hayley E Fitzgerald, David Rosenfield, Joseph K Carpenter, Santiago Papini, Christina D Dutcher, Sheila M Dowd, Stefan G Hofmann, Mark H Pollack, Jasper A J Smits and 1 more

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Mechanisms of Change in Exposure Therapy for Anxiety and Related Disorders: A Research Agenda.Clinical psychological science : a journal of the Association for Psychological Science · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Rebecca E LubinDepartment of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave, 2nd Fl, Boston, MA, 02215, USA. Electronic address: rlubin@bu.edu.
Hayley E FitzgeraldDepartment of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave, 2nd Fl, Boston, MA, 02215, USA.
David RosenfieldDepartment of Psychology, Southern Methodist University, 6116 North Central Expressway, Dallas, TX, 75206, USA.
Joseph K CarpenterNational Center for Posttraumatic Stress Disorder, Women's Health Sciences Division, 150 S Huntington Ave, Boston, MA, 02130, USA; VA Boston Healthcare System, 150 S Huntington Ave, Boston, MA, 02130, USA; Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, 72 E Concord St, Boston, MA, 02118, USA.
Santiago PapiniDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Christina D DutcherInstitute of Mental Health Research and Department of Psychology, The University of Texas at Austin, 108 E Dean Keeton St, Austin, TX, 78712, USA.
Sheila M DowdDepartment of Psychiatry and Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Blvd Suite 400, Chicago, IL, 60612, USA.
Stefan G HofmannDepartment of Clinical Psychology, Philipps University Marburg, Schulstrasse 12, 35037, Marburg/Lahn, Germany.
Mark H PollackDepartment of Psychiatry and Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Blvd Suite 400, Chicago, IL, 60612, USA; Sage Therapeutics, 215 First St, Cambridge, MA, 02142, USA.
Jasper A J SmitsInstitute of Mental Health Research and Department of Psychology, The University of Texas at Austin, 108 E Dean Keeton St, Austin, TX, 78712, USA.
Michael W OttoDepartment of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave, 2nd Fl, Boston, MA, 02215, USA.
Boston University · USRush University Medical Center · USThe University of Texas at Austin · USKaiser Permanente · USPhilipps University of Marburg · DESouthern Methodist University · US

Funding

Connectomes Related to Anxiety and Depression in AdolescentsU01MH108168 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIELI, JOHN, WHITFIELD-GABRIELI, SUSAN · 2015 to 2019
$4.6M
Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social AnxietyR01MH128377 · NIMH · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI DANIEL G DILLON, JOHN GABRIELI · 2022 to 2026
$4.3M
2/3-Dose Timing of D-cycloserine to Augment CBT for Social Anxiety DisorderR34MH099311 · NIMH · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI HOFMANN, STEFAN G. · 2014 to 2016
$737k
Dose Timing of D-cycloserine to Augment CBT for Social Anxiety DisorderR34MH099309 · NIMH · RUSH UNIVERSITY MEDICAL CENTER · PI POLLACK, MARK H · 2014 to 2016
$698k
3/3-Dose Timing of D-cycloserine to Augment CBT for Social Anxiety DisorderR34MH099318 · NIMH · UNIVERSITY OF TEXAS AT AUSTIN · PI SMITS, JASPER · 2014 to 2016
$695k
NIMH NIH HHS R01 MH128377NIMH NIH HHS R34 MH099309NIMH NIH HHS R34 MH099311NIMH NIH HHS R34 MH099318NIMH NIH HHS U01 MH108168
6 · The paper itself

Abstract

backgroundOver a decade and a half of research has resulted in inconsistent evidence for the efficacy of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, for augmenting exposure-based cognitive behavioral therapy (CBT) for anxiety- and fear-based disorders. These variable findings have motivated the search for moderators of DCS augmentation efficacy.

methodsIn this secondary analysis of a previous randomized clinical trial, we evaluated the value of de novo threat conditioning outcomes-degree of threat acquisition, extinction, and extinction retention-for predicting treatment response to exposure-based CBT for social anxiety disorder, applied with and without DCS augmentation in a sample of 59 outpatients.

resultsWe found that average differential skin conductance response (SCR) during extinction and extinction retention significantly moderated the prediction of clinical response to DCS: participants with poorer extinction and extinction retention showed relatively improved treatment response with DCS. No such effects were found for expectancy ratings, consistent with accounts of DCS selectively aiding lower-order but not higher-order extinction learning.

conclusionsThese findings provide support for extinction and extinction retention outcomes from threat conditioning as potential pre-treatment biomarkers for DCS augmentation benefits. Independent of DCS augmentation, the current study did not support threat conditioning outcomes as useful for predicting response to exposure-based CBT.

Indexed as

Cognitive Behavioral TherapyCycloserineAnxiety DisordersCombined Modality TherapyExtinction, PsychologicalHumansTreatment OutcomeCycloserineCBTD-cycloserineExtinctionExtinction retentionSocial anxiety disorderThreat conditioning

Identifiers

PMID37399757
PMCPMC10557473
OpenAlexW4381185996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.